Scheduling (national classification system)
Scheduling is a national classification system that controls how medicines and chemicals are made available to the consumers in order to protect public health.
Medicines and chemicals are classified into Schedules according to the level of regulatory control over the availability of the medicine or chemical required to protect public health and safety. The Schedules are published in the Poisons Standard and are given legal effect through state and territory legislation.
For details go to Scheduling of medicines & poisons.
Key information
Scheduling
- Scheduling basics
- Advisory Committee on Chemicals Scheduling
- Advisory Committee on Medicines Scheduling
- Public notices about scheduling
- Update on Psilocybin and MDMA scheduling
- Implementation of decisions and actions following the review of chemical scheduling in relation to cosmetic and fragrance ingredients
- Scheduling legislation
- Scheduling news
Poisons Standard
- Introduction to the Poisons Standard
- The Poisons Standard (the SUSMP)
- AHMAC - Scheduling policy framework for medicines and chemicals
- Scheduling handbook: Guidance for amending the Poisons Standard
State and territory information
- State/Territory scheduling information
- Contacts for State/Territory medicines & poisons regulation units
- Australian State & Territory regulatory controls on Schedule 7 poisons
- Australian State & Territory variations from Part 4 of the Poisons Standard
Amending the Poisons Standard and consultation coversheets
- Scheduling handbook: Guidance for amending the Poisons Standard
- Application to amend the Poisons Standard
- Scheduling consultation coversheets
Reports
- Independent Expert Panel on MDMA and psilocybin
- Independent expert report on the risks of intentional self-poisoning with paracetamol
- An evaluation of the therapeutic value, benefits and risks of methylenedioxymethamphetamine (MDMA) and psilocybin for the treatment of mental, behavioural or developmental disorders
- Regulatory options for appropriate access and safety controls for alkyl nitrites - Public meeting questions and answers
Latest articles
-
Therapeutic Goods (Poisons Standard) (Benzylpenicillin—Seqirus) Approval 2024
This instrument is the Therapeutic Goods (Poisons Standard) (Benzylpenicillin—Seqirus) Approval 2024. -
Changes to choline salicylate access to start from 1 October 2023
Find out about changes to choline salicylate access, starting from October 2023. -
Update on MDMA and psilocybin access and safeguards from 1 July 2023
Stay updated about the commencement of MDMA and psilocybin for the treatment of certain mental illnesses.
Latest publications
-
Find out about the public submissions on interim decisions for scheduling matters referred to the ACMS #44, ACCS #38 and Joint ACMS-ACCS #36 meetings held in March 2024
-
Publication of the decisions made by a delegate of the Secretary in relation to glycopyrronium and palmitoylethanolamide.
-
This web publication constitutes a notice for the purposes of regulations 42ZCZS and 42ZCZX of the Therapeutic Goods Regulations 1990 (the Regulations).